Soliris - 2007 FDA approvals

Drug: Soliris (eculizumab)
Indication: Paroxysmal nocturnal hemoglobinuria
Company: Alexion
Approval Date: March 16, 2007

Scoop: Soliris is a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria--a disease in which the immune system attacks the body's own red blood cells.

More news:
Alexion's eculizumab succeeds in Phase III. Report
Alexion shares surge on eculizumab data. Report

Soliris - 2007 FDA approvals
Read more on

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.